Hidradenitis Suppurativa, Hyperhidrosis
Conditions
Brief summary
This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.
Detailed description
Botulinum toxin prevents vesicle fusion at nerve terminals thereby inhibiting neuropeptide release. The investigators will collect punch biopsies of lesional skin from HS patients before, and 1-2 months after botulinum toxin treatment (50U per axilla in 10 injections of 0.1mL) then perform flow cytometric, transcriptomic, and microscopic analysis of skin to determine if nonselective inhibition of neuropeptide release diminishes IL-17 driven skin inflammation.
Interventions
DRUGBotulinum toxin
Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin
Sponsors
University of Massachusetts, Worcester
Hidradenitis Suppurativa Foundation
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
AbbVie
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Inclusion: * Adults between ages 18 and 75 years with established diagnosis of hidradenitis suppurativa (HS) * HS skin lesions of duration at least 1 year, HS skin lesions in at least two different body areas Exclusion: * Age \< 18 years or \> 75 years * pregnant or breastfeeding * neuromuscular disorder (ex. ALS, myasthenia gravis, Lambert-Eaton syndrome, myopathy) * medical co-morbidity that is a relative contraindication to skin biopsy procedure (ex. end stage congestive heart failure or coagulopathy) * active bacterial, fungal, or viral infection in the treatment area * known hypersensitivity to botulinum toxin A preparations or any of their components (human albumin, saline, lactose, sodium succinate) * prisoners * adults unable to consent for themselves.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Quantification and phenotyping of skin resident dendritic cell, macrophage, and T cell populations in patients before and after intralesional Botox treatment. | 1-2 months after first treatment | immune cell phenotyping |
Countries
United States
Contacts
CONTACTSarah K Whitley, MD PhD
CONTACTDeborah White, Deborah Peduzzi
PRINCIPAL_INVESTIGATORSarah K Whitley, MD PhD
Assistant Professor of Dermatology
Outcome results
None listed